Insight

Tandem autologous stem cell transplantation does not benefit high-risk myeloma patients

Photo taken from newatlas.com

Jul 10, 2024, 00:53

Tandem autologous stem cell transplantation does not benefit high-risk myeloma patients

at Alfaisal University, shared a paper by Christopher P Venner et al. on X:

“Tandem autologous stem cell transplantation does not benefit high-risk myeloma patients in the maintenance era:

Real-world results from the canadian myeloma research group database.”

Source: Mostafa Faisal/X

Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients In The Maintenance Era: Real-world Results From The Canadian Myeloma Research Group Database.

Authors: Christopher P Venner, Peter Duggan, Kevin Song, Donna Reece, Smriti Sharma, Jiandong Su, Victor H Jimenez-Zepeda, Arleigh McCurdy, Martha Louzada, Hira Mian, Michael Sebag, Darrell White, Julie Stakiw, Rami Kotb, Muhammad Aslam, Anthony Reiman, Engin Gul, Michael P Chu, Debra Bergstrom and Richard LeBlanc.

Alfaisal University Anthony Reiman Arleigh McCurdy cancer Christopher P Venner Darrell White Debra Bergstrom Donna Reece Engin Gul Hira Mian Jiandong Su Julie Stakiw Kevin Song Martha Louzada Michael P Chu Michael Sebag Mostafa Faisal Muhammad Aslam Myeloma myeloma patients myeloma research OncoDaily Oncology Peter Duggan Rami Kotb Richard LeBlanc Smriti Sharma Stem Cell Victor H Jimenez-Zepeda

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage